Polarean Imaging: Positive results from pivotal trials (from yesterday) | Beximco Pharmaceuticals (BXP.L): Half-year results show double digit growth (from yesterday) | Novacyt plc (NCYT): Full-year trading update (from Tuesday) | Fusion Antibodies (FAB.L): Strong revenues in Q3 trading (from yesterday)
30 Jan 2020
SP Angel Healthcare Conditions-30-01-2020
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
SP Angel Healthcare Conditions-30-01-2020
Polarean Imaging Plc (POLX:LON), 4.3 | Beximco Pharmaceuticals Limited Sponsored GDR RegS (BXP:LON), 39.0 | Novacyt SAS (NCYT:LON), 44.2 | Fusion Antibodies Plc (FAB:LON), 3.8
- Published:
30 Jan 2020 -
Author:
Vadim Alexandre | Liam Gascoigne-Cohen -
Pages:
3
Polarean Imaging: Positive results from pivotal trials (from yesterday) | Beximco Pharmaceuticals (BXP.L): Half-year results show double digit growth (from yesterday) | Novacyt plc (NCYT): Full-year trading update (from Tuesday) | Fusion Antibodies (FAB.L): Strong revenues in Q3 trading (from yesterday)